Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
NCT ID: NCT00345761
Last Updated: 2010-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
64 participants
INTERVENTIONAL
2006-02-28
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00416494
Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
NCT00159432
Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer
NCT00120172
1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
NCT00345696
First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer
NCT03451370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Step 1
Oxaliplatin
130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
Capecitabine
2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
Step 2
Bevacizumab
7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
Oxaliplatin
130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
Capecitabine
2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
Step 3
Bevacizumab
7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
Oxaliplatin
130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
Capecitabine
2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
Oxaliplatin
130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
Capecitabine
2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed colorectal cancer
* Metastatic and/or locally advanced colorectal cancer not previously treated with chemotherapy for metastatic disease
* At least one measurable lesion according to RECIST
Exclusion Criteria
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study; fine needle aspiration within 7 days prior to study treatment start.
* Evidence of bleeding diathesis or coagulopathy
* Serious, non-healing wound, ulcer, or bone fracture
* Chronic, daily aspirin (\> 325 mg/day), anticoagulants, or other medications known to predispose to gastrointestinal ulceration
20 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yakult Honsha Co., LTD
INDUSTRY
Chugai Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chugai Pharmaceutical CO.,LTD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuji Hayashi
Role: STUDY_CHAIR
Clinical Development Department 3, Group 6
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hokkaido Region
Hokkaido, Hokkaido, Japan
Kanto Region
Kanto, Kanto, Japan
Kinki Region
Kinki, Kinki, Japan
Tokai Region
Tōkai, Tokai, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JO19380
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.